← Eichor
Condition: Relapsed Refractory Multiple Myeloma Or Plasma Cell Leukemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapsed Refractory Multiple Myeloma Or Plasma Cell Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04603872A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
EARLY_Phase 1 · 1 location(s) · Hrain Biotechnology Co., Ltd. · NCT06045091IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
Phase 2 · 1 location(s) · The First Hospital of Jilin University · NCT07509086Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Phase 1 · 1 location(s) · Chunrui Li · NCT05219721Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
NA · 1 location(s) · Anhui Provincial Hospital · NCT06961669a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
EARLY_Phase 1 · 1 location(s) · Shanghai Changzheng Hospital · NCT06718270A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
EARLY_Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06730256A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Phase 1 · 1 location(s) · Nanjing IASO Biotechnology Co., Ltd. · NCT05759793
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.